KRAS, NRAS and BRAF are oncogenes frequently somatically mutated in colorectal tumours. Somatic KRAS, NRAS and BRAF mutations result in a specific gain of function and almost exclusively affect codons 12, 13 and 61 of the KRAS and NRAS genes and codon 600 of BRAF. As KRAS, NRAS and BRAF lie downstream of EGFR in the EGFR signalling pathway, presence of an activating KRAS, NRAS or BRAF mutation in a colorectal tumour predicts a likely poor response to anti-EGFR monoclonal antibodies. Frequency of KRAS, NRAS, BRAF mutations in colorectal cancer (CRC) samples is approximately 36–40%, 1-6% and 8–15% respectively.
Please refer to the National Genomic Test Directory for Cancer here
Salvage pathway targeted testing 7 calendar days
Panel Test 21 calendar days
Please refer to our Sample Requirements section before sending any samples to us for testing.